Investment
Features
FeesSafety
Academy
More
Pluang+

Compare Datadog Inc (DDOG) vs Viatris Inc (VTRS) Price & Performance

Datadog IncTrade
Viatris IncTrade

Price performance (Past 24H)

Key statistics

Datadog Inc vs Viatris Inc — how do they compare? Datadog Inc trades at $273.66 (market cap $98.31B), while Viatris Inc trades at $17.49 (market cap $20.03B). The key difference: Datadog Inc is far larger — about 4.9× Viatris Inc's market cap, and Viatris Inc pays a 2.75% dividend while Datadog Inc pays none. Which is the better fit depends on your goals — on Pluang, investors hold Datadog Inc for 76 Days and Viatris Inc for 57 Days on average.

DDOGVTRS
Market Cap
$98.31B$20.03B
Volume
2,936,66014,109,977
Sector
TechnologyHealth
52-Week High
$288.15$18.27
52-Week Low
$102.62$9.74
Typical Hold Time
76 Days57 Days
Enterprise Value
$94.61B$32.15B
Dividend Yield
—2.75%

Aura AI Summary

Signals from Pluang's Aura AI — not financial advice

Datadog Inc

Datadog (DDOG) trades at $271.34, down 2.48% on the day but remains near its 52-week high. The stock exhibits a bullish technical trend with strong moving average signals, while oscillators are neutral. Fundamentally, revenue growth is robust, rising from $1.7B in 2022 to $3.43B in 2025, though net income margins are volatile. Recent earnings beats and accelerating enterprise customer adoption, particularly in AI and cloud observability, support positive sentiment.

The outlook is favorable given analyst consensus and AI-driven demand, but high valuation multiples (P/E 542.68) and negative net cash flow pose risks. Upside potential exists if the company sustains earnings momentum and expands profitability. Key risks include competitive pressures and execution challenges in a high-growth environment.

Viatris Inc

Viatris (VTRS) trades at $17.49, down 0.29% with a bullish technical signal and strong recent earnings beats. The company shows improving operational cash flow of $2.32B in 2025 and positive revenue growth trends, though profitability remains challenged with negative net margins. Recent developments include FDA approval for WAKIX in Japan and consistent dividend payments, supporting the bullish analyst consensus with a $22.17 price target representing 27% upside potential.

The outlook remains cautiously optimistic with strong cash generation supporting shareholder returns, but investors face risks from persistent negative profitability and high debt levels. The stock offers value appeal with reasonable P/S and P/B ratios, though the elevated P/E ratio reflects current earnings challenges that need resolution for sustained re-rating.

Returns comparison

Trailing returns across standard periods

Investor sentiment on Pluang

What Pluang investors did over the last 30 days

DDOG
47% Buy53% Sell
Avg holding period · 76 Days
VTRS

No sentiment data available yet.

Top news

Latest headlines on both assets

About Datadog Inc

Datadog is a cloud-native company that focuses on analyzing machine data. The firm's product portfolio, delivered as software-as-a-service, allows a client to monitor and analyze its entire IT infrastructure. Datadog's platform can ingest and analyze large amounts of machine-generated data in real time, allowing clients to utilize it for a variety of different applications throughout their businesses.

Read more on DDOG →

About Viatris Inc

Formed by the combination of Mylan and Pfizer's Upjohn business in 2020, Viatris is one of the world's largest generic drug manufacturers, with a substantial off-patent branded drug portfolio. Its portfolio consists of more than 1,400 molecules with penetration across most of the developed world and in select emerging markets. The company's branded drug portfolio consists of off-patent blockbuster drugs that continue to generate strong sales, including Lipitor, Norvasc, Lyrica, Viagra, and EpiPen. While global competition has facilitated the commodification of small-molecule generic drugs, the company has demonstrated an edge over peers in its ability to manufacture complex generics (for example, generic Advair and Copaxone).

Read more on VTRS →